The majority of business interest is in seasonal and pandemic vaccines, but as the public health argument for influenza B intervention is becoming more apparent so companies are expressing an interest in developing universal vaccines and antivirals. However, whilst interest in Type B antigen development is evident among global vaccine manufacturers, details from public sources are opaque. RA Partners conducted a global market assessment of therapeutics and vaccines targeting influenza B, cross-checking public sources against private and manufacturer opinion. Conflicting evidence was frequently found and the scarcity of public information on the development of vaccines with a specific Type B component was found. The picture for neuraminidase inhibitor focussed antivirals in clinical development was found to be fractionally less opaque than for vaccines.